Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Influence of Alzheimer's associated Aβ oligomers and oxidative stress on blood-brain barrier dysfunction.

Tissue barriers·2025

Same author

Predicting Transvaginal Surgical Mesh Exposure Outcomes Using an Integrated Dataset of Blood Cytokine Levels and Medical Record Data: Machine Learning Approach.

JMIR formative research·2025

Same author

Full-dose challenge of moderate, severe, and unknown beta-lactam allergies in the emergency department.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine·2024

Same author

Modulating the RAGE-Induced Inflammatory Response: Peptoids as RAGE Antagonists.

Chembiochem : a European journal of chemical biology·2023

Same author

Human <i>in vitro</i> blood barrier models: architectures and applications.

Tissue barriers·2023

Same author

Prediction of Pelvic Organ Prolapse Postsurgical Outcome Using Biomaterial-Induced Blood Cytokine Levels: Machine Learning Approach.

JMIR perioperative medicine·2023

Search research articles

Related Experiment Video

Updated: Jun 27, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Rationally Designed Peptoid Inhibitors of Amyloid-β Oligomerization.

Mihyun Lim Waugh¹, Lauren M Wolf¹, Kelly A Moore¹

¹Department of Biomedical Engineering, University of South Carolina, 3A46 Swearingen Engineering Center, Columbia, SC 29208, USA.

Chembiochem : a European Journal of Chemical Biology

|May 7, 2024

Summary

This study shows that a peptoid molecule, JPT1, can inhibit the formation of toxic amyloid-beta (Aβ) oligomers, a key factor in Alzheimer's disease progression. JPT1 also reduces Aβ-induced inflammation in brain cells, suggesting therapeutic potential.

Keywords:

Alzheimer's disease aggregation amyloid-β peptides oligomerization peptoid

More Related Videos

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids

Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids

Published on: March 21, 2025

Related Experiment Videos

Last Updated: Jun 27, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids

Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids

Published on: March 21, 2025

Area of Science:

Neuroscience
Biochemistry
Drug Discovery

Background:

Soluble amyloid-beta (Aβ) oligomers are more neurotoxic than fibrillar plaques in Alzheimer's disease (AD).
Targeting Aβ oligomerization is a promising therapeutic strategy for AD.

Purpose of the Study:

To investigate the efficacy of a peptoid mimic (JPT1) of the Aβ KLVFF core in inhibiting Aβ oligomerization.
To explore the role of linker charge in JPT1's interaction with Aβ.
To assess the impact of JPT1 on Aβ-induced neuroinflammation.

Main Methods:

Synthesis and characterization of the peptoid JPT1.
In vitro studies on Aβ oligomerization modulation.
Cell-based assays using SH-SY5Y neuroblastoma cells to measure nuclear factor-κB (NF-κB) activation.

Main Results:

JPT1 effectively modulates Aβ oligomerization.
The charge of the linker influences JPT1's activity.
JPT1 treatment attenuates Aβ oligomer-induced NF-κB activation in neuronal cells.

Conclusions:

Peptoid JPT1 demonstrates therapeutic potential for inhibiting toxic Aβ oligomer formation.
JPT1 can mitigate Aβ-induced neuroinflammatory responses, offering a novel therapeutic avenue for Alzheimer's disease.